Fariyal Ahmed is Head of Business Development and Translational Medicine at Singapore Immunology Network (SIgN), A*STAR (Singapore). The group focuses on strategic alliance with industry, clinical and academic partners, life cycle management, human ethics and intellectual property valorization. Prior to joining A*STAR, Fariyal was a scientist at Baxter International Inc. (Chicago), where she led several global cross functional strategy projects and was awarded Baxter’s Corporate Technical award in 2012. She completed her PhD in Bioengineering from the University of Pennsylvania in 2005. She is a co-inventor of a patent with Dr Dennis Discher (UPENN; Philadelphia). As a postdoctoral fellow in Dr Judy Lieberman’s lab at the Immune Disease Institute, Harvard Medical School (Boston), she was awarded two fellowships from Center for AIDS Research and Canadian Institutes of Health Research for work on immune checkpoint inhibitors in HIV.
The Translational Immunology Group was created in 2009 to support the implementation of translational and applied research within SIgN. Activities include:
- Business development and follow-up of collaborations with industry
- Project/platform management and documentation
- Facilitation of clinical research studies
- IP valorization
- Academic contracts negotiation
The Group also helps in planning and managing the development of drug leads originated from SIgN discovery research, such as fully human antibodies, up to the stage of Preclinical Development Candidate.
|Business Development and
Translational Project Managers
|Technology Platform Manager
||Siew Min FOO
| || || Siew Min ONG